Intra-arterial treatment with 90Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 12, 2011, Pages 2117-2124

  Lambert, Bieke ^a   Sturm, Emiel ^a   Mertens, Jeroen ^a   Oltenfreiter, Ruth ^a   Smeets, Peter ^a   Troisi, Roberto ^a   Van Vlierberghe, Hans ^a   Defreyne, Luc ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

90Y; Hepatocellular carcinoma (HCC); Liver; Microspheres; Selective internal radiation therapy (SIRT)

Indexed keywords

BILIRUBIN; MACROSALB TC 99M; MICROSPHERE Y 90; RADIOACTIVE MICROSPHERE; THERASPHERE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; ASCITES; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERBILIRUBINEMIA; LIVER CELL CARCINOMA; LONG TERM SURVIVAL; MALE; RETROSPECTIVE STUDY; TREATMENT RESPONSE; URINARY EXCRETION;

AGED; AGED, 80 AND OVER; BELGIUM; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; INJECTIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; LONGITUDINAL STUDIES; MALE; MICROSPHERES; MIDDLE AGED; RADIOPHARMACEUTICALS; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84856222494     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1881-2     Document Type: Article

References (23)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76. (Pubitemid 46890874)
2. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005;25:181-200. (Pubitemid 40781071)
3. Llovet JM, Fuster J, Bruix J, Barcelona-Clinic Liver Cancer Group. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004;10:S115-20. (Pubitemid 38240111)
4. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9. (Pubitemid 26079803)
5. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48:S20-37.
6. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
7. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-38.
8. Raoul JL, Guyader D, Bretagne JF, Heautot JF, Duvauferrier R, Bourguet P, et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997;26:1156-61. (Pubitemid 27509297)
9. Gulec SA, Siegel JA. Posttherapy radiation safety considerations in radiomicrosphere treatment with 90Y-microspheres. J Nucl Med 2007;48:2080-6. (Pubitemid 350232320)
10. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-30. (Pubitemid 32844200)
11. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.
12. The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998;28:751-5.
13. Ahmadzadehfar H, Möhlenbruch M, Sabet A, Meyer C, Muckle M, Haslerud T, et al. Is prophylactic embolization of the hepatic falciform artery needed before radioembolization in patients with (99m) Tc-MAA accumulation in the anterior abdominal wall? Eur J Nucl Med Mol Imaging 2011;38:1477-84.
14. Hilgard P, Hamami M, Fouly AE, Scherag A, Müller S, Ertle J, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010;52:1741-9.
15. Sangro B, Bilbao JI, Boan J, Martinez-Cuesta A, Benito A, Rodriguez J, et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2006;66:792-800. (Pubitemid 44436697)
16. Iñarrairaegui M, Thurston KG, Bilbao JI, D'Avola D, Rodriguez M, Arbizu J, et al. Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2010;21:1205-12.
17. Riaz A, Lewandowski RJ, Kulik LM, Mulcahy MF, Sato KT, Ryu RK, et al. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol 2009;20:1121-30.
18. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of longterm outcomes. Gastroenterology 2010;138:52-64.
19. Gulec SA, Sztejnberg ML, Siegel JA, Jevremovic T, Stabin M. Hepatic structural dosimetry in (90) Y microsphere treatment: a Monte Carlo modeling approach based on lobular microanatomy. J Nucl Med 2010;51:301-10.
20. Riaz A, Miller FH, Kulik LM, Nikolaidis P, Yaghmai V, Lewandowski RJ, et al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA 2010;303:1062-9.
21. Coldwell DM, Kennedy AS, Nutting CW. Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer. Int J Radiat Oncol Biol Phys 2007;69:800-4. (Pubitemid 47418394)
22. Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona Clinic Liver Cancer stages: a European evaluation. Hepatology 2011 May 26. doi:10.1002/hep. 24451. [Epub ahead of print].
23. Lewandowski RJ, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009;9:1920-8.